Clene Inc. (CLNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clene Inc. (CLNN) has a cash flow conversion efficiency ratio of 0.104x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.59 Million) by net assets ($-24.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Clene Inc. for the company's overall valuation and market capitalisation.
Clene Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Clene Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Clene Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clene Inc. ranked by their cash flow conversion efficiency. Explore Clene Inc. cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Akin Tekstil AS
IS:ATEKS
|
0.001x |
|
Rank Progress S.A.
WAR:RNK
|
0.006x |
|
Francotyp-Postalia Holding AG
F:FPH
|
0.005x |
|
Grand Hall Enterprise Co Ltd
TWO:8941
|
0.077x |
|
Tevogen Bio Holdings Inc.
NASDAQ:TVGN
|
0.338x |
|
FreeCast, Inc. Class A Common Stock
NASDAQ:CAST
|
0.408x |
|
SMCore.Inc
KQ:007820
|
-0.082x |
|
Carlos Casado
BA:CADO
|
0.014x |
Annual Cash Flow Conversion Efficiency for Clene Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Clene Inc. from 2018 to 2025. View current stock price of Clene Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-17.59 Million | $-18.55 Million | 1.054x | -56.22% |
| 2024-12-31 | $-8.86 Million | $-21.33 Million | 2.408x | +206.86% |
| 2023-12-31 | $13.39 Million | $-30.17 Million | -2.253x | +81.30% |
| 2022-12-31 | $3.24 Million | $-39.01 Million | -12.052x | -338.46% |
| 2021-12-31 | $12.60 Million | $-34.62 Million | -2.749x | +95.05% |
| 2020-12-31 | $341.00K | $-18.93 Million | -55.510x | -1955.61% |
| 2019-12-31 | $4.89 Million | $-13.20 Million | -2.700x | -6474.48% |
| 2018-12-31 | $5.00 Million | $-205.37K | -0.041x | -- |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral … Read more